|
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results showed that the AD patients had more Treg cells than the TD patients or controls (C group) and also had elevated levels of expression of regulatory markers (glucocorticoid-induced tumor necrosis factor [TNF] receptor-related protein [GITR], CTLA-4, CD95L, LAP-1, and CD38).
|
20643858 |
2010 |
|
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cox regression analysis showed that high serum sTNFR1 levels predicted the conversion from MCI to AD (p = 0.003), whereas no significant differences were found with respect to serum levels of TNF-α and sTNFR2.
|
20930310 |
2010 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This suggests that genetic alteration in TNF gene may play a role in AD.
|
20693638 |
2010 |
|
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Differential TNF receptor protein levels and binding affinities suggest distinct pathogenic mechanisms of neurodegeneration in the AD brain.
|
20110607 |
2010 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The minor allele of rs1468063 in the FAS gene, which is member 6 of the tumor necrosis factor receptor superfamily, was significantly associated with faster AD progression after adjustment for multiple testing (P(permutation) = 0.049).
|
19766542 |
2010 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because MCP-1 and TNF-α play important roles in maintaining the synaptic network in PCs, the present study suggests that atorvastatin and pitavastatin can maintain the number of PCs and their synaptic networks in the AD cerebellum.
|
21419111 |
2011 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, our results demonstrate that globally ablated TNF receptor signaling exacerbates pathogenesis and argues against long-term use of pan-anti-TNF-α inhibitors for the treatment of AD.
|
21835156 |
2011 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The association among single nucleotide polymorphisms in inflammatory genes as interleukin-1 alpha (IL-1α), interleukin-1 beta (IL-1β) or tumor necrosis factor alpha (TNF-α) and dementia has been explored mostly in Alzheimer's disease, while few data addressing their association with dementia in very old people are available.
|
21509504 |
2012 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is associated with an altered immune response, resulting in chronic increased inflammatory cytokine production with a prominent role of TNF-α.
|
22441986 |
2012 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To investigate the effect of early immune modulation on neuroinflammation and cognitive outcome, we treated triple transgenic Alzheimer's disease mice (harboring PS1(M146V), APP(Swe), and tau(P301L) transgenes) with the small molecule tumor necrosis factor-α inhibitors, 3,6'-dithiothalidomide and thalidomide, beginning at four months of age.
|
22632257 |
2012 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, these results do not support the hypothesis that the A allele of G-308A TNF-α gene polymorphism is associated either with AD or T2D.
|
22580620 |
2012 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Inheritance of the TNF-α (-863) C allele has been associated with an elevated risk of Alzheimer disease.
|
22509108 |
2012 |
|
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Both cannabinoids were effective at reducing the enhancement of COX-2 protein levels and TNF-α mRNA expression found in the AD model.
|
22248049 |
2012 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A number of genetic risk factors have been identified for Alzheimer's disease (AD) including genes involved in the inflammatory response (interleukin 1A, [IL-1α (-889)], interleukin 1B (IL-1β [+3953]), and tumor necrosis factor (TNF [-308 and -850]).
|
20961668 |
2012 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our finding that blood Zn, TNF-α, and total Aβ are possible biomarkers for AD diagnosis and prognosis validates the pervious publication on potential biomarker in the Taiwanese population.
|
23230229 |
2013 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD11b labeling indicated changes in microglial morphology toward an activated state, suggesting that these cells may be a putative source of the observed TNFα increase during this pre-symptomatic stage of AD-like pathology.
|
23579326 |
2013 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor receptor II (TNFRII) is one of the TNF receptor superfamily members and our recent pathological studies show that TNFRII is deficient in the brains of Alzheimer's disease (AD).
|
24824215 |
2014 |
|
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In 43 cognitively intact older adults (79.3±4.8 years) and 39 patients with AD (81.9±5.1 years at the time of MRI) participating in the Cardiovascular Health Study, we examined year-1 reported physical activity intensity, year-5 blood serum TNFα measures, and year-9 volumetric brain MRI scans.
|
24836855 |
2014 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the potential adverse effects of TNF-based AD therapies have been of concerns, here we summarize recent discoveries relating to TNF and TNFRI-mediated signal transduction as potential therapeutic targets in AD pathology and clinical investigations.
|
24998784 |
2014 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A significant hypomethylation of the TNF-α promoter was found in AD patients' brains but not in their blood.
|
24556805 |
2014 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CSF levels of AD-related biomarkers (Aβ42, p-tau, total tau), non-AD-related Aβ isoforms (Aβ38, Aβ40), sAPP isoforms (sAPPα, sAPPβ), proinflammatory cytokines (several interleukins (IL), interferon-gamma, monocyte chemoattractant protein-1, tumor necrosis factor-alpha) and biomarkers of neuronal damage (neurofilament light and myelin basic protein) were measured.All patients were genotyped for APOE.
|
24638077 |
2014 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To determine factors that induce CAP37 in AD, HCN-1A primary human neurons were treated with tumor necrosis factor-alpha (TNF-α) or amyloid β1-40 (Aβ) and analyzed by IHC.
|
26170148 |
2015 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, a significant protective effect of TNF-alpha -308A was found in the occurrence of AD among North European populations under a dominant model.
|
25735998 |
2015 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further we observed that the monocytes of AD mice and of AD patients were significantly more vulnerable to cell damage (as seen by 7-AAD incorporation in FACS analysis) and displayed an enhanced release of pro-inflammatory cytokines (MIP2 and TNFα).
|
26159193 |
2015 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The overall variation of the haplotypes formed by the RAGE and TNF and HSP70 variants influenced the presence of the AD phenotype (omnibus association LR test p-value 0.00185), HSP701 and HSP702 showed independent effect on AD risk after adjusting for the effect of the entire haplotype (conditional LR test p-value=0.0114 and p-value=0.0044 respectively).
|
26502815 |
2015 |